Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-01EMA Authorised: Velmetia (sitagliptin;metformin hydrochloride) — Merck Sharp & Dohme B.V.
The EMA has authorised Velmetia, a fixed-dose combination of sitagliptin and metformin hydrochloride, for the treatment of type 2 diabetes m…
-
EMA approval · 2025-12-01EMA Authorised: Tesavel (sitagliptin) — Merck Sharp & Dohme B.V.
The EMA authorised Tesavel (sitagliptin) by Merck Sharp & Dohme B.V. for treatment of type 2 diabetes mellitus in the European Union.
-
EMA approval · 2025-12-01EMA Authorised: Xelevia (sitagliptin) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Xelevia (sitagliptin) for the treatment of Type 2 diabetes mellitus. The product is marketed by Mer…
-
EMA approval · 2025-11-21EMA Authorised: Steglujan (ertugliflozin l-pyroglutamic acid;sitagliptin phosphate monohydrate) — Merck Sharp & Dohme B.V.
EMA authorised Steglujan, a fixed-dose combination tablet of ertugliflozin and sitagliptin, for type 2 diabetes mellitus in the EU, issued t…
-
EMA approval · 2025-11-21EMA Authorised: Segluromet (ertugliflozin l-pyroglutamic acid;metformin hydrochloride) — Merck Sharp & Dohme B.V.
The EMA authorised Segluromet, a fixed-dose combination of ertugliflozin and metformin, for the treatment of type 2 diabetes in adults.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-19EMA Authorised: Synjardy (empagliflozin;metformin) — Boehringer Ingelheim
The European Medicines Agency authorised Synjardy (empagliflozin/metformin) for the treatment of type 2 diabetes mellitus.
-
EMA approval · 2025-11-17EMA Authorised: Awiqli (insulin icodec) — Novo Nordisk A/S
EMA authorised Awiqli (insulin icodec) from Novo Nordisk A/S for the treatment of diabetes, including type 2 diabetes.
-
EMA approval · 2025-11-17EMA Authorised: Ristfor (sitagliptin;metformin hydrochloride) — Merck Sharp & Dohme B.V.
The EMA authorised Ristfor, a fixed-dose combination of sitagliptin and metformin hydrochloride, for adults with type 2 diabetes mellitus.
-
EMA approval · 2025-11-13EMA Authorised: Janumet (sitagliptin;metformin hydrochloride) — Merck Sharp & Dohme B.V.
EMA has authorised Janumet (sitagliptin and metformin) for the treatment of type 2 diabetes mellitus.
-
FDA approval · 2025-11-10FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved Granules Pharmaceuticals Inc.'s supplemental application for metformin hydrochloride granules, adding an approved generic metfo…
-
EMA approval · 2025-11-10EMA Authorised: Sitagliptin SUN (sitagliptin fumarate) — Sun Pharmaceutical Industries Europe B.V.
The EMA authorised Sitagliptin SUN (sitagliptin fumarate) for treating Type 2 diabetes mellitus. The marketing authorization holder is Sun P…
-
FDA approval · 2025-11-03FDA Approved: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for a generic fixed-dose combination of linagliptin and metformin hydrochloride (Novadoz Pharmaceutica…
-
EMA approval · 2025-10-31EMA Authorised: Januvia (sitagliptin) — Merck Sharp and Dohme B.V
EMA has authorized Januvia (sitagliptin) for type 2 diabetes mellitus. Merck Sharp & Dohme B.V. is the marketing authorization holder.
-
EMA approval · 2025-10-30EMA Authorised: Ristaben (sitagliptin) — Merck Sharp & Dohme B.V.
The EMA authorised Ristaben, a sitagliptin product by Merck Sharp & Dohme B.V., for treatment of type 2 diabetes mellitus.
-
FDA approval · 2025-10-24FDA Approved: TRIJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for TRIJARDY XR, a fixed-dose combination of empagliflozin, linagliptin, and metformin hydrochloride…
-
FDA approval · 2025-10-17FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Ozempic to include the oral semaglutide formulation, expanding treatment options to patients…
-
FDA approval · 2025-10-15FDA Approved: LIRAGLUTIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for liraglutide from Meitheal Pharmaceuticals Inc.
-
FDA approval · 2025-10-14FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for XULTOPHY 100/3.6 (insulin degludec and liraglutide) by Novo Nordisk. The product is indicated fo…
-
EMA approval · 2025-09-30EMA Authorised: Sitagliptin / Metformin hydrochloride Mylan (sitagliptin hydrochloride monohydrate;metformin hydrochloride) — Mylan Pharmaceuticals Limited
The EMA authorised a fixed-dose combination of sitagliptin and metformin hydrochloride from Mylan for the treatment of type 2 diabetes melli…
-
FDA approval · 2025-09-02FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for BYETTA (exenatide) submitted by AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2025-08-27FDA Approved: LIRAGLUTIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approves Teva's liraglutide generic under Original Application (ANDA 214568). The approval covers the same indications as the reference …
-
EMA approval · 2025-07-25EMA Authorised: Vildagliptin / Metformin hydrochloride Accord (metformin hydrochloride;vildagliptin) — Accord Healthcare S.L.U.
The EMA authorised a fixed-dose combination of vildagliptin and metformin hydrochloride (Accord) for adults with type 2 diabetes mellitus.
-
FDA approval · 2025-07-22FDA Approved: LIRAGLUTIDE — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' generic liraglutide (Original Application), making a generic injectable GLP-1 receptor agonist avail…
-
FDA approval · 2025-07-01FDA Approved: REPAGLINIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application from Chartwell RX, LLC for repaglinide, enabling the generic version of the drug to be marketed.
-
EMA approval · 2025-06-10EMA Authorised: Vokanamet (canagliflozin;metformin hydrochloride) — Janssen-Cilag International NV
The EMA authorised Vokanamet, a fixed-dose combination tablet of canagliflozin and metformin hydrochloride, for type 2 diabetes mellitus; ma…